{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T08:19:52Z","timestamp":1766391592844,"version":"3.30.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,29]]},"DOI":"10.7759\/cureus.74768","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T18:58:32Z","timestamp":1732906712000},"source":"Crossref","is-referenced-by-count":1,"title":["Intravenous Efgartigimod Alfa as Initial Monotherapy for Disabling Ocular Myasthenia in an Elderly Patient with Multiple Comorbidities"],"prefix":"10.7759","author":[{"given":"Karen","family":"Inzirillo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Octavio","family":"Carranza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc A","family":"Swerdloff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1573-2","article-title":"Understanding side effects of therapy for myasthenia gravis and their impact on daily life","volume":"19","author":"Bacci ED","year":"2019","unstructured":"Bacci ED, Coyne KS, Poon JL, Harris L, Boscoe AN. Understanding side effects of therapy for myasthenia gravis and their impact on daily life. BMC Neurol. 2019, 19:335. 10.1186\/s12883-019-1573-2","journal-title":"BMC Neurol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061597","article-title":"Current treatment of myasthenia gravis","volume":"11","author":"Alhaidar MK","year":"2022","unstructured":"Alhaidar MK, Abumurad S, Soliven B, Rezania K. Current treatment of myasthenia gravis. J Clin Med. 2022, 11:1597. 10.3390\/jcm11061597","journal-title":"J Clin Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2022-000241","article-title":"New and emerging treatments for myasthenia gravis","volume":"2","author":"DeHart-McCoyle M","year":"2023","unstructured":"DeHart-McCoyle M, Patel S, Du X. New and emerging treatments for myasthenia gravis. BMJ Med. 2023, 2:e000241. 10.1136\/bmjmed-2022-000241","journal-title":"BMJ Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.596981","article-title":"Myasthenia gravis: autoantibody specificities and their role in MG management","volume":"11","author":"Lazaridis K","year":"2020","unstructured":"Lazaridis K, Tzartos SJ. Myasthenia gravis: autoantibody specificities and their role in MG management. Front Neurol. 2020, 11:596981. 10.3389\/fneur.2020.596981","journal-title":"Front Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008903","article-title":"Clinical and therapeutic features of myasthenia gravis in adults based on age at onset","volume":"94","author":"Cort\u00e9s-Vicente E","year":"2020","unstructured":"Cort\u00e9s-Vicente E, \u00c1lvarez-Velasco R, Segovia S, et al.. Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology. 2020, 94:e1171-80. 10.1212\/WNL.0000000000008903","journal-title":"Neurology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-023-01000-z","article-title":"Efgartigimod alfa in generalised myasthenia gravis: a profile of its use","volume":"37","author":"Heo YA","year":"2023","unstructured":"Heo YA. Efgartigimod alfa in generalised myasthenia gravis: a profile of its use. CNS Drugs. 2023, 37:467-73. 10.1007\/s40263-023-01000-z","journal-title":"CNS Drugs"},{"key":"ref7","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.96.15_supplement.1817","article-title":"The evolution of myasthenia gravis-activities of daily living (MG-ADL) scale utilization to measure myasthenia gravis symptoms and treatment response.","volume":"96","author":"Muppidi S","year":"2021","unstructured":"Muppidi S, Silvestri N, Tan R, Riggs K, Leighton T. The evolution of myasthenia gravis-activities of daily living (MG-ADL) scale utilization to measure myasthenia gravis symptoms and treatment response.. Neurology. 2021, 96:","journal-title":"Neurology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13588","article-title":"Very late onset of myasthenia gravis. Comment: comorbidities in older patients with myasthenia gravis","volume":"145","author":"Hernandez Fustes OJ","year":"2022","unstructured":"Hernandez Fustes OJ. Very late onset of myasthenia gravis. Comment: comorbidities in older patients with myasthenia gravis. Acta Neurol Scand. 2022, 145:786. 10.1111\/ane.13588","journal-title":"Acta Neurol Scand"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami P","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, et al.. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021, 96:114-22. 10.1212\/WNL.0000000000011124","journal-title":"Neurology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/312698-intravenous-efgartigimod-alfa-as-initial-monotherapy-for-disabling-ocular-myasthenia-in-an-elderly-patient-with-multiple-comorbidities","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T18:58:33Z","timestamp":1732906713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/312698-intravenous-efgartigimod-alfa-as-initial-monotherapy-for-disabling-ocular-myasthenia-in-an-elderly-patient-with-multiple-comorbidities"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.74768","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,29]]}}}